ESR1 and breast cancer: Indeed, CAF-derived CXCL-14 expression was correlated with shorter recurrence-free survival in estrogen receptor negative, triple negative, and basal-like BC (Sjöberg et al., 2016), as well as in additional tumor types (reviewed in Westrich et al., 2020).